05 dec, 2017 - The European Investment Bank (EIB) and Grifols signed today an Euros 85 million loan to support the company's R+D+i initiatives focused on investigating new indications for plasma-derived protein therapies to treat rare and chronic diseases.
26 oct, 2017 - Grifols would like to make it clear that the rumours circulating regarding a possible sponsorship and stadium naming deal between F.C. Barcelona and the company are entirely unfounded. The company is not considering any sponsorship deal of this kind.
22 sep, 2017 - Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. The new formulation marks an important milestone in Grifols' ongoing R&D efforts
23 jun, 2017 - Grifols Launches New Therapeutic Drug Monitoring Testing Services for the Biologic Drugs Infliximab, Adalimumab and Vedolizumab